Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 52-Week High - Time to Buy?

Key Points

• Adaptive Biotechnologies shares reached a new 52-week high of $26.49, supported by a consensus “Moderate Buy” rating from analysts and an average price target of $24.42, though the stock is already trading above that average target.
• The company’s latest quarter showed 21.5% year-over-year revenue growth to $71.55 million, beating estimates, but its $0.25 per-share loss was wider than expected and profitability remains negative.
• Insiders have sold significant amounts of stock—more than $46.6 million over the past 90 days—while institutional investors own 99.17% of shares, highlighting strong institutional participation alongside notable insider selling.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $26.49 and last traded at $26.2190, with a volume of 196608 shares traded. The stock had previously closed at $25.55.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. BTIG Research raised their price objective on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Piper Sandler upped their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an "overweight" rating in a research report on Tuesday, August 4th. Morgan Stanley raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 30th. Guggenheim lifted their price objective on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has a consensus rating of "Moderate Buy" and an average target price of $24.42.

Adaptive Biotechnologies Stock Up 3.0%

The stock has a market cap of $4.20 billion, a PE ratio of -64.16 and a beta of 2.08. The business has a 50 day simple moving average of $22.22 and a 200 day simple moving average of $17.39. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.12). The business had revenue of $71.55 million during the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. Adaptive Biotechnologies's revenue was up 21.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.17) earnings per share. On average, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current fiscal year.

Insider Buying and Selling at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Francis Lo sold 51,004 shares of the business's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $22.45, for a total transaction of $1,145,039.80. Following the completion of the transaction, the insider owned 237,688 shares of the company's stock, valued at $5,336,095.60. The trade was a 17.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad M. Robins sold 321,324 shares of the business's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $25.08, for a total value of $8,058,805.92. Following the transaction, the chief executive officer directly owned 2,180,518 shares of the company's stock, valued at $54,687,391.44. This represents a 12.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,062,325 shares of company stock worth $46,659,069 in the last 90 days. Company insiders own 5.70% of the company's stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

Hedge funds have recently modified their holdings of the business. AQR Capital Management LLC increased its position in Adaptive Biotechnologies by 45.8% during the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company's stock worth $2,265,000 after acquiring an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Adaptive Biotechnologies by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company's stock worth $511,000 after purchasing an additional 2,914 shares during the period. Caxton Associates LLP bought a new position in shares of Adaptive Biotechnologies during the 1st quarter worth about $93,000. New York State Common Retirement Fund raised its position in shares of Adaptive Biotechnologies by 39.2% during the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company's stock valued at $551,000 after buying an additional 13,300 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Adaptive Biotechnologies by 728.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company's stock valued at $4,417,000 after buying an additional 333,379 shares during the last quarter. 99.17% of the stock is owned by institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source